Retinal Vein Occlusion Market Research Report - Forecast till 2027

Retinal Vein Occlusion Market: Information By Type (Branch Retinal Artery Occlusion and Central Retinal Vein Occlusion), By Condition (Non-Ischemic and Ischemic), Diagnosis (Optical Coherence Tomography, Fundoscopic Examination and Fluorescein Angiography), Treatment (Antivascular Endothelial Growth Factor, Corticosteroid Drugs and Laser Retinal Photocoagulation), End User (Hospitals and Clinics and Research & Academics Centers) - Forecast till 2027

ID: MRFR/Pharma/3934-CR | July 2019 | Region: Global | 150 Pages         

1 Report Prologue

2 Market Introduction

2.1 Definition 19

2.2 Scope of Study 19

2.3 Research Objective 19

2.4 Assumptions & Limitations 20

2.4.1 Assumptions 20

2.4.2 Limitations 20

2.5 Market Structure 20

3 Research Methodology

3.1.1 Primary Research Methodology 22

3.1.2 Secondary Research Methodology 23

3.1.3 Market Share Analysis 23

3.1.4 Market Pricing Approach 23

4 Market Dynamics

4.1 Introduction 25

4.2 Drivers 26

4.2.1 Increasing Prevalence of Diabetes and Atherosclerosis (Impact Weightage 40%) 26

4.2.2 Change in Lifestyle (Impact Weightage 35%) 27

4.2.3 Increasing Prevalence of Glaucoma, Lymphoma, and Multiple Myeloma (Impact Weightage 25%) 28

4.3 Restraints 29

4.3.1 Side Effect of Treatment (Impact Weightage 60%) 29

4.3.2 High Cost of Treatment (Impact Weightage 40%) 30

5 Market Factor Analysis

5.1 Porters Five Forces Model 31

5.1.1 Bargaining Power of Suppliers 32

5.1.2 Bargaining Power of Buyers 32

5.1.3 Threat of New Entrants 32

5.1.4 Threat of Substitutes 32

5.1.5 Intensity of Rivalry 33

5.2 Value Chain Analysis 33

5.2.1 R&D 33

5.2.2 Manufacturing 34

5.2.3 Distribution & Sales 34

5.2.4 Post–sales Monitoring 34

5.3 Demand & Supply: Gap Analysis 35

5.4 Pricing Analysis 35

5.5 Investment Opportunity Analysis 35

6 Global Retinal Vein Occlusion Market, By Type

6.1 Branch Retinal Artery Occlusion 37

6.2 Central Retinal Vein Occlusion 37

7 Global Retinal Vein Occlusion Market, By Condition

7.1 Non–Ischemic 39

7.2 Ischemic 39

8 Global Retinal Vein Occlusion Market, By Diagnosis

8.1 Optical Coherence Tomography 41

8.2 Fundoscopic Examination 41

8.3 Fluorescein Angiography 42

9 Global Retinal Vein Occlusion Market, By Treatment

9.1 Antivascular Endothelial Growth Factor 44

9.1.1 Aflibercept 44

9.1.2 Ranibizumab 45

9.2 Corticosteroid Drugs 45

9.2.1 Triamcinolone Acetonide 46

9.2.2 Dexamethasone 46

9.3 Laser Retinal Photocoagulation 47

10 Global Retinal Vein Occlusion Market, By End User

10.1 Hospitals and Clinics 49

10.2 Research & Academics Centers 49

11 Global Retinal Vein Occlusion Market, By Region

11.1 Americas 50

11.1.1 North America 54

11.1.1.1 U.S 57

11.1.1.2 Canada 60

11.1.2 South America 63

11.2 Europe 66

11.2.1 Western Europe 70

11.2.1.1 Germany 74

11.2.1.2 France 77

11.2.1.3 UK 80

11.2.1.4 Italy 83

11.2.1.5 Spain 86

11.2.1.6 Rest of Western Europe 89

11.2.2 Eastern Europe 92

11.3 Asia–Pacific 96

11.3.1 Japan 101

11.3.2 China 104

11.3.3 India 107

11.3.4 Australia 110

11.3.5 Republic of Korea 113

11.3.6 Rest of Asia–Pacific 116

11.4 Middle East & Africa 120

11.4.1 Africa 128

12 Competitive Landscape

12.1 Introduction 131

12.2 Company Share Analysis 131

13 Company Profiles

13.1 Allergan PLC 132

13.1.1 Company Overview 132

13.1.2 Financials 132

13.1.3 Products 132

13.1.4 Strategy 132

13.1.5 Key Developments 132

13.2 Bayer 133

13.2.1 Company Overview 133

13.2.2 Financials 133

13.2.3 Products 133

13.2.4 Strategy 133

13.2.5 Key Developments 133

13.3 Bristol–Myers Squibb 134

13.3.1 Company Overview 134

13.3.2 Financials 134

13.3.3 Products 134

13.3.4 Strategy 134

13.3.5 Key Developments 134

13.4 Ellex Medical Lasers Ltd. 135

13.4.1 Company Overview 135

13.4.2 Financials 135

13.4.3 Products 135

13.4.4 Strategy 135

13.4.5 Key Developments 135

13.5 GlaxoSmithKline PLC 136

13.5.1 Company Overview 136

13.5.2 Financials 136

13.5.3 Products 136

13.5.4 Strategy 136

13.5.5 Key Developments 136

13.6 IRIDEX Corporation 137

13.6.1 Company Overview 137

13.6.2 Financials 137

13.6.3 Products 137

13.6.4 Strategy 137

13.6.5 Key Developments 137

13.7 Lumenis 138

13.7.1 Company Overview 138

13.7.2 Financials 138

13.7.3 Products 138

13.7.4 Strategy 138

13.7.5 Key Developments 138

13.8 Novartis 139

13.8.1 Company Overview 139

13.8.2 Financials 139

13.8.3 Products 139

13.8.4 Strategy 139

13.8.5 Key Developments 139

13.9 NIDEK CO., LTD. 140

13.9.1 Company Overview 140

13.9.2 Financials 140

13.9.3 Products 140

13.9.4 Strategy 140

13.9.5 Key Developments 140

13.10 Regeneron Pharmaceuticals 141

13.10.1 Company Overview 141

13.10.2 Financials 141

13.10.3 Products 141

13.10.4 Strategy 141

13.10.5 Key Developments 141

13.11 F. Hoffmann–La Roche AG 142

13.11.1 Company Overview 142

13.11.2 Financials 142

13.11.3 Products 142

13.11.4 Strategy 142

13.11.5 Key Developments 142

13.12 Quantel Medical Inc. 143

13.12.1 Company Overview 143

13.12.2 Financials 143

13.12.3 Products 143

13.12.4 Strategy 143

13.12.5 Key Developments 143

13.13 Topcon Medical Systems, Inc. 144

13.13.1 Company Overview 144

13.13.2 Financials 144

13.13.3 Products 144

13.13.4 Strategy 144

13.13.5 Key Developments 144

13.14 ZEISS 145

13.14.1 Company Overview 145

13.14.2 Financials 145

13.14.3 Products 145

13.14.4 Strategy 145

13.14.5 Key Developments 145

14 MRFR Conclusion

14.1 Key Findings 146

14.1.1 From CEO’s View Point 146

14.1.2 Unmet Needs 146

14.2 Key companies to watch 146

15 Appendix

15.1 Discussion Blue Print 147

16 List of Tables

TABLE 1 PRIMARY INTERVIEWS 22

TABLE 2 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR BRANCH RETINAL ARTERY OCCLUSION, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 3 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 4 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR NON–ISCHEMIC, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 5 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR ISCHEMIC, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 6 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2020–2027 (USD MILLION) 41

TABLE 7 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR FUNDOSCOPIC EXAMINATION, BY REGION, 2020–2027 (USD MILLION) 41

TABLE 8 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR FLUORESCEIN ANGIOGRAPHY, BY REGION, 2020–2027 (USD MILLION) 42

TABLE 9 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 10 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR AFLIBERCEPT, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 11 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR RANIBIZUMAB, BY REGION, 2020–2027 (USD MILLION) 45

TABLE 12 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR CORTICOSTEROID DRUGS, BY REGION, 2020–2027 (USD MILLION) 45

TABLE 13 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR TRIAMCINOLONE ACETONIDE, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 14 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR DEXAMETHASONE, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 15 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR LASER RETINAL PHOTOCOAGULATION, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 16 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2020–2027 (USD MILLION) 49

TABLE 17 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR RESEARCH & ACADEMICS CENTERS, BY REGION, 2020–2027 (USD MILLION) 49

TABLE 18 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY REGION, 2020–2027 (USD MILLION) 51

TABLE 19 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 51

TABLE 20 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 51

TABLE 21 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 52

TABLE 22 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 52

TABLE 23 AMERICAS ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 24 AMERICAS CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 25 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 53

TABLE 26 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 54

TABLE 27 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 28 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 54

TABLE 29 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 55

TABLE 30 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 55

TABLE 31 NORTH AMERICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 32 NORTH AMERICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 33 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 56

TABLE 34 US RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 35 US RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 57

TABLE 36 US RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 57

TABLE 37 US RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 58

TABLE 38 US ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 39 US CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 40 US RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 59

TABLE 41 CANADA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 42 CANADA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 60

TABLE 43 CANADA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 60

TABLE 44 CANADA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 61

TABLE 45 CANADA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 46 CANADA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 47 CANADA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 62

TABLE 48 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 49 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 63

TABLE 50 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 64

TABLE 51 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 64

TABLE 52 SOUTH AMERICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 53 SOUTH AMERICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 54 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 65

TABLE 55 EUROPE RETINAL VEIN OCCLUSION MARKET, BY REGION, 2020–2027 (USD MILLION) 67

TABLE 56 EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 57 EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 67

TABLE 58 EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 68

TABLE 59 EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 68

TABLE 60 EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 61 EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 62 EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 69

TABLE 63 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 70

TABLE 64 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 65 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 71

TABLE 66 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 71

TABLE 67 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 72

TABLE 68 WESTERN EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 69 WESTERN EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 70 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 73

TABLE 71 GERMANY RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 72 GERMANY RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 74

TABLE 73 GERMANY RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 74

TABLE 74 GERMANY RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 75

TABLE 75 GERMANY ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 76 GERMANY CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 76

TABLE 77 GERMANY RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 76

TABLE 78 FRANCE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 79 FRANCE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 77

TABLE 80 FRANCE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 77

TABLE 81 FRANCE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 78

TABLE 82 FRANCE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 83 FRANCE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 84 FRANCE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 79

TABLE 85 UK RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 86 UK RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 80

TABLE 87 UK RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 80

TABLE 88 UK RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 81

TABLE 89 UK ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 90 UK CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 91 UK RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 82

TABLE 92 ITALY RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 83

TABLE 93 ITALY RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 83

TABLE 94 ITALY RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 83

TABLE 95 ITALY RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 84

TABLE 96 ITALY ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 97 ITALY CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 98 ITALY RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 85

TABLE 99 SPAIN RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 86

TABLE 100 SPAIN RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 86

TABLE 101 SPAIN RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 86

TABLE 102 SPAIN RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 87

TABLE 103 SPAIN ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 104 SPAIN CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 105 SPAIN RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 88

TABLE 106 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 107 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 89

TABLE 108 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 90

TABLE 109 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 90

TABLE 110 REST OF WESTERN EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 111 REST OF WESTERN EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 112 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 92

TABLE 113 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

TABLE 114 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 93

TABLE 115 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 93

TABLE 116 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 94

TABLE 117 EASTERN EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 94

TABLE 118 EASTERN EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 95

TABLE 119 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 95

TABLE 120 ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 97

TABLE 121 ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 97

TABLE 122 ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 98

TABLE 123 ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 98

TABLE 124 ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 99

TABLE 125 ASIA-PACIFIC ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 99

TABLE 126 ASIA-PACIFIC CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 100

TABLE 127 ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 100

TABLE 128 JAPAN RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 129 JAPAN RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 101

TABLE 130 JAPAN RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 101

TABLE 131 JAPAN RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 102

TABLE 132 JAPAN ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 102

TABLE 133 JAPAN CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 103

TABLE 134 JAPAN RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 103

TABLE 135 CHINA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 136 CHINA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 104

TABLE 137 CHINA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 104

TABLE 138 CHINA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 105

TABLE 139 CHINA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 105

TABLE 140 CHINA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 106

TABLE 141 CHINA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 106

TABLE 142 INDIA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 107

TABLE 143 INDIA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 107

TABLE 144 INDIA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 107

TABLE 145 INDIA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 108

TABLE 146 INDIA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 108

TABLE 147 INDIA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 109

TABLE 148 INDIA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 109

TABLE 149 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 110

TABLE 150 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 110

TABLE 151 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 110

TABLE 152 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 111

TABLE 153 AUSTRALIA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 111

TABLE 154 AUSTRALIA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112

TABLE 155 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 112

TABLE 156 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 113

TABLE 157 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 113

TABLE 158 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 114

TABLE 159 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 114

TABLE 160 REPUBLIC OF KOREA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 115

TABLE 161 REPUBLIC OF KOREA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 115

TABLE 162 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 116

TABLE 163 REST OF ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 116

TABLE 164 REST OF ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 116

TABLE 165 REST OF ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 117

TABLE 166 REST OF ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 117

TABLE 167 REST OF ASIA-PACIFIC ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 118

TABLE 168 REST OF ASIA-PACIFIC CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 118

TABLE 169 REST OF ASIA-PACIFIC RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 119

TABLE 170 THE MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY REGION, 2020–2027 (USD MILLION) 121

TABLE 171 THE MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 121

TABLE 172 THE MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 122

TABLE 173 THE MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, AW2020–2027 (USD MILLION) 122

TABLE 174 THE MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 123

TABLE 175 THE MIDDLE EAST & AFRICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 123

TABLE 176 THE MIDDLE EAST & AFRICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 124

TABLE 177 THE MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 124

TABLE 178 THE MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 125

TABLE 179 THE MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 125

TABLE 180 THE MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 125

TABLE 181 THE MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 126

TABLE 182 THE MIDDLE EAST ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 126

TABLE 183 THE MIDDLE EAST CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 127

TABLE 184 THE MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 127

TABLE 185 AFRICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020–2027 (USD MILLION) 128

TABLE 186 AFRICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020–2027 (USD MILLION) 128

TABLE 187 AFRICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 128

TABLE 188 AFRICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 129

TABLE 189 AFRICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2020–2027 (USD MILLION) 129

TABLE 190 AFRICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 130

TABLE 191 RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020–2027 (USD MILLION) 130

17 List of Figures

FIGURE 1 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020 (%) 16

FIGURE 2 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020 (%) 16

FIGURE 3 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020 (%) 17

FIGURE 4 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020 (%) 17

FIGURE 5 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020 (%) 18

FIGURE 6 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY REGION, 2020 (%) 18

FIGURE 7 MARKET STRUCTURE OF GLOBAL RETINAL VEIN OCCLUSION MARKET 20

FIGURE 8 RESEARCH METHODOLOGY 21

FIGURE 9 GLOBAL RETINAL VEIN OCCLUSION MARKET: FORECAST MODEL 24

FIGURE 10 PORTER’S FIVE FORCES MODEL 31

FIGURE 11 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 36

FIGURE 12 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2020 & 2027 (USD MILLION) 38

FIGURE 13 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2020 & 2027 (USD MILLION) 40

FIGURE 14 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2020 & 2027 (USD MILLION) 43

FIGURE 15 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY END USER, 2020 & 2027 (USD MILLION) 48

Retinal Vein Occlusion Market Speak to Analyst Request a Free Sample

Retinal Vein Occlusion Market Overview


Retinal Vein Occlusion Market, according to MRFR, is expected to register a CAGR of 11.2% to reach USD 15.88 Billion till 2023. Market development is projected to increase the prevalence of diabetes, shift in lifestyle, and increase the occurrence of glaucoma, lymphoma, and multiple myeloma worldwide.


COVID-19 Analysis of Retinal Vein Occlusion Market


The reduction is largely due to the epidemic of COVID-19, which has led to stringent containment initiatives including social distancing, remote jobs, and closing factories and other economic operations, resulting in organisational difficulties. The whole supply chain has been affected, adversely affecting the market.


Market Dynamics


Drivers


Growing Prevalence of Eye Diseases to Fuel Market Growth


The major factors of the retinal vein occlusion market are the rise in prevalence of eye diseases worldwide, increase in geriatric population, increase in understanding of eye disorders, strengthened health care facilities, technological developments, and upcoming novel therapies. The presence of a powerful pipeline and recent drug approvals will fuel the growth of the retinal vein occlusion market. The number of cases of retinal vein occlusion is increasing and there is an increase in the number of molecules under research for treatment. The efficacy of retinal vein occlusion therapy is rising with the presence of a strong pipeline and recent drug approvals. This, in essence, would fuel business growth by embracing retinal vein occlusion therapeutics.


Opportunities


Growing R&D investments to Create Growth Avenues for the Key Players


The global retinal vein occlusion therapeutics industry is positively influenced by developments in drug delivery technology. There are many benefits of innovative drug delivery systems, including decreases in the amount and duration of doses needed to maintain the optimal clinical response, reduced health care costs, and preferential patient compliance. In retinal vein occlusion therapeutics, such benefits would improve end-user demand for innovative drug delivery technologies, driving market development.


Increases in research and investment are expected to build business prospects for the creation of safe and economical therapies by market players.


Restraints


High Treatment-Related Costs Impedes Market Growth


However, the demand is expected to be hampered by the current unmet needs existing in the retinal vein occlusion market for care aimed at restoring vision and at the same time being affordable. There is no question that demand growth is projected to decrease in the forecast timeframe with the introduction of biosimilars into the Retinal vein occlusion market. High treatment-related costs and associated side effects of these therapies are expected to hamper demand development during the forecast period.


Retinal Vein Occlusion Market Segmental Analysis


By Type


The retinal vein occlusion market, by type, has been bifurcated into branch retinal artery occlusion and central retinal vein occlusion.


By Condition


The retinal vein occlusion industry has been defined as non-ischemic and ischemic based on condition.


By Diagnosis


Based on diagnosis, the retinal vein occlusion market has been categorised as optical coherence tomography, fundoscopic examination, fluorescein angiography, and others. During the forecast era, the optical coherence tomography (OCT) segment is projected to rise.


By Treatment


By treatment, has been segmented into antivascular corticosteroid drugs, endothelial growth factor, laser retinal photocoagulation, and others.


By End-User


The industry has been divided into hospitals and clinics, research & academic centres, and others dependent on end-users. A significant factor in the growth of the hospitals & clinics market is a strong preference for hospitals by the increasing elderly population.


Retinal Vein Occlusion Market  Regional Analysis


The geographical overview of the global retinal vein occlusion market has been conducted in four major regions, including the Asia Pacific, North America, Europe, and the rest of the world.


North America leads the Americas with established end-use Sectors


It is estimated that the Americas will have the highest share of the global demand for retinal vein occlusion. North America, primarily because of the growing prevalence of diabetes and the increasing occurrence of diseases such as glaucoma, lymphoma, and multiple myeloma, is expected to lead the market. Due to the rising prevalence of patients, the occurrence of main business players, and the production of surgical outcomes, the region of the Americas also dominates the retinal vein occlusion market. The demand in the area is further bolstered by additional factors, such as the effect of a good economic situation and the focus of academic institutions on upgrading technologies for modern and innovative treatment methods for retinal vein occlusion.


Germany to Lead Europe Market


During the projection period, Europe is projected to account for the second-largest market share. The emergence of a large geriatric population and high healthcare expenditure are the factors responsible for retinal vein occlusion market growth in this region.


APAC to account as Fastest Growing Region


Due to the presence of a significant diabetes patient population, Asia-Pacific is expected to be the fastest-growing region on the global retinal vein occlusion market, the presence of immense market expansion opportunities fuels the growth of the Asia-Pacific retinal vein occlusion market. Due to a rising number of developing nations present in this region, such as nations like China and India, the Asia Pacific region is also the fastest growing retinal vein occlusion market.


MEA Region Driven by Development of the Healthcare Sector


Due to the existence of a well-developed healthcare system, the retinal vein occlusion market in the Middle East & Africa is anticipated to expand. Due to restricted connectivity to medical facilities and the slower development of the healthcare sector, the MEA market is likely to experience gradual growth. However, nations like Kuwait and Qatar are relying more on the healthcare sector and emerging medical facilities, which will improve the region's market.


Competitive Landscape


Key Players focus on Mergers & Acquisitions to Expand their Business Standing


The Retinal Vein Occlusion sector has also become a very dynamic industry and this factor is advantageous to the market analysed as firms gain opportunity to develop their presence. In addition, major market players are concentrating on the extension of their regional presence. The major market players are likely to engage in collaborations, mergers & acquisitions, and product launches to expand their presence in the market and provide effective and reachable patient care.



  • Allergan PLC

  • Bayer

  • Bristol-Myers Squibb

  • Ellex Medical Lasers Ltd

  • GlaxoSmithKline PLC

  • IRIDEX Corporation

  • Lumenis

  • Novartis AG

  • NIDEK CO., LTD

  • Regeneron Pharmaceuticals

  • Hoffmann-La Roche AG

  • Quantel Medical Inc.

  • Topcon Medical Systems, Inc.

  • ZEISS


Recent Development


December 2020: Arctic Vision, a clinical-stage ophthalmology company headquartered in China with a leading pipeline of breakthrough innovations, announced the approval of the Phase III Investigational New Drug (IND) for the treatment of Uveitic Macular Edema. It was China's first clinical trial for UME therapy and for suprachoroidal space (SCS) injection, which was supposed to include a new treatment choice for UME patients in China.


December 2020: Novartis confirmed promising findings from the first interpretable Phase III results of a clinical trial examining the effectiveness and safety of Beovu. Novartis's Beovu gave Regeneron's an anti-VEGF Eylea, one of the leading therapies to improve diabetic macular edema, close competition.


Report Overview


By Type



  • Branch Retinal Artery Occlusion

  • Central Retinal Vein Occlusion


By Condition



  • Non-Ischemic

  • Ischemic


By Diagnosis



  • Optical Coherence Tomography

  • Fundoscopic Examination

  • Fluorescein Angiography

  • Others


By Treatment



  • Antivascular Endothelial Growth Factor

  • Corticosteroid Drugs

  • Laser Retinal Photocoagulation

  • Others


By End-User



  • Hospitals and Clinics

  • Research & Academics Centers

  • Others



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 15.88 Billion
  • 2027: Significant Value
  •   CAGR   11.2% (2017-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Condition, Diagnosis, Treatment, End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Allergan PLC, Bayer, Bristol-Myers Squibb, Ellex Medical Lasers Ltd, GlaxoSmithKline PLC, IRIDEX Corporation, Lumenis, Novartis AG, NIDEK CO., LTD, Regeneron Pharmaceuticals, Hoffmann-La Roche AG, Quantel Medical Inc., Topcon Medical Systems, Inc., ZEISS
      Key Market Opportunities   Growing R&D investments to Create Growth Avenues for the Key Players
      Key Market Drivers   Growing Prevalence of Eye Diseases


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Retinal Vein Occlusion Market can register a CAGR of 11.2% from 2020 to 2027.

    Retinal Vein Occlusion Market size can touch USD 15,889.59 million by 2023.

    Prevalence of diabetes, cases of myeloma and glaucoma, and changing lifestyles of patients are major drivers of the Global Retinal Vein Occlusion Market.

    High costs of treatment and its adverse effects can hamper the Global Retinal Vein Occlusion Market growth.

    GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Lumenis, IRIDEX Corporation, Regeneron Pharmaceuticals, Bayer, Novartis AG, Allergan PLC, Ellex Medical Lasers Ltd, Bristol-Myers Squibb, Quantel Medical Inc., NIDEK CO., LTD, Topcon Medical Systems, Inc., and ZEISS are prominent players of the Global Retinal Vein Occlusion Market.